Sorrento Therapeutics Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
116.73 M |
Public Float |
111.35 M |
Sorrento Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$2.43 |
Market Cap |
$295.55 M |
Shares Outstanding |
122.63 M |
Public Float |
95.18 M |
Address |
4955 Directors Place San Diego California 92121 United States |
Employees | - |
Website | http://www.sorrentotherapeutics.com |
Updated | 07/08/2019 |
Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. The company was founded by Henry H. |